FDA approves first Neulasta® (pegfilgrastim) and Procrit® (epoetin alfa) biosimilars and second Neupogen® (filgrastim biosimilar)...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
BiosimilarsIP.com Regulatory provides articles about regulatory issues and events related to biologics and biosimilars from the FDA, the EMA and other international agencies.
-
-
European Medicines Agency approves second trastuzumab and third insulin glargine biosimilars FDA has not approved any biosimilar...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
U.S. Food & Drug Administration and European Medicines Agency approve first trastuzumab biosimilars U.S. Food & Drug...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On January 3, 2018, Momenta and Mylan announced their development plan for a proposed biosimilar to Regeneron’s Eylea® whose active...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
European Medicines Agency newly approves two adalimumab biosimilars U.S. Food & Drug Administration approves first bevacizumab...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
According to a new report by RAND Corporation, biosimilars could save $54 billion in healthcare spending on biologics over the next ten...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
European Medicines Agency newly approves five rituximab biosimilars and an etanercept biosimilar, while recommending approval of...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]